Clinical observation of capecitabine and temozolomide in the treatment of advanced pancreatic neuroendocrine tumors
10.3969/j.issn.1000-8179.2017.05.404
- VernacularTitle:卡培他滨联合替莫唑胺治疗晚期胰腺神经内分泌肿瘤的临床观察
- Author:
Qing LIU
;
Pan ZHANG
;
Jie LUO
;
Dou DOU
;
Huangying TAN
- Keywords:
pancreatic neuroendocrine neoplasm;
temozolomide;
progress-free survival;
adverse effect
- From:
Chinese Journal of Clinical Oncology
2017;44(5):228-232
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the therapeutic effect and toxicity of capecitabine and temozolomide in the treatment of advanced pancreatic neuroendocrine tumors. Methods:A total of 14 patients with stageⅣwell-differentiated pancreatic neuroendocrine tumor (NET G1/G2/G3) were treated with oral CAPTEM regimen, and the response rate, PFS and adverse effect after treatment were analyzed. All data analyses were performed using software SPSS17.0. Results:These 14 patients were followed-up for more than 2 years. Till Oct 2016, one patient got CR, one patient got PR, four patients got SD. Median progression-free survival was 8.9 months. The two year survival rate was 85.7%. Only one patient experienced grade 3 adverse events. Conclusion:CAPTEM is an effective and well-tolerated salvage regimen for the treatment of advanced well-differentiated pNET.
